Alnylam Sweden AB
559086-6686ActiveLeading RNAi therapeutics company developing gene-silencing medicines.
Biopharmaceutical Companyalnylam.se
Yleiskatsaus
- 5–9
- Työntekijät
- 100–500milj SEK
- Liikevaihto
- 2016
- Perustettu
Avainpäättäjät
Christine Akinc
Chief Corporate Communications Officer
Jeff Poulton
Chief Financial Officer
Hiroshi Okada
President, Alnylam Japan
Bryan Supran
Chief Legal Officer
+19 lisää yhteystietoja Funnelfeedrissä
Kuvaus
Alnylam Pharmaceuticals is a leading global biopharmaceutical company dedicated to pioneering RNA interference (RNAi) therapeutics. They focus on developing an innovative class of medicines designed to treat diseases by silencing the specific genes responsible for causing them. This mechanism target...